135 related articles for article (PubMed ID: 21854813)
1. Isoforms of Pax5 and co-regulation of T- and B-cells associated genes influence phenotypic traits of ascetic cells causing Dalton's lymphoma.
Bharti B; Mishra R
Biochim Biophys Acta; 2011 Dec; 1813(12):2071-8. PubMed ID: 21854813
[TBL] [Abstract][Full Text] [Related]
2. Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.
Bharti B; Shukla S; Tripathi R; Mishra S; Kumar M; Pandey M; Mishra R
Indian J Med Res; 2016 May; 143(Supplement):S23-S31. PubMed ID: 27748274
[TBL] [Abstract][Full Text] [Related]
3. Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells.
Arseneau JR; Laflamme M; Lewis SM; Maïcas E; Ouellette RJ
Br J Haematol; 2009 Nov; 147(3):328-38. PubMed ID: 19725825
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of Dalton's lymphoma-induced angiogenesis by melatonin.
Kumari R; Rawat K; Kumari A; Shrivastava A
Tumour Biol; 2017 Jun; 39(6):1010428317705758. PubMed ID: 28618962
[TBL] [Abstract][Full Text] [Related]
5. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers.
Hansson M; Jerkeman M; Dictor M
Eur J Haematol; 2007 Aug; 79(2):159-65. PubMed ID: 17635241
[TBL] [Abstract][Full Text] [Related]
6. Spleen-specific isoforms of Pax5 and Ataxin-7 as potential proteomic markers of lymphoma-affected spleen.
Bharti B; Mishra R
Mol Cell Biochem; 2015 Apr; 402(1-2):181-91. PubMed ID: 25573326
[TBL] [Abstract][Full Text] [Related]
7. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.
Cozma D; Yu D; Hodawadekar S; Azvolinsky A; Grande S; Tobias JW; Metzgar MH; Paterson J; Erikson J; Marafioti T; Monroe JG; Atchison ML; Thomas-Tikhonenko A
J Clin Invest; 2007 Sep; 117(9):2602-10. PubMed ID: 17717600
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.
Walter K; Cockerill PN; Barlow R; Clarke D; Hoogenkamp M; Follows GA; Richards SJ; Cullen MJ; Bonifer C; Tagoh H
Oncogene; 2010 May; 29(20):2927-37. PubMed ID: 20208555
[TBL] [Abstract][Full Text] [Related]
9. Identification and comparative analysis of Pax5 C-terminal isoforms expressed in human cord blood-derived B cell progenitors.
Sekine R; Kitamura T; Tsuji T; Tojo A
Immunol Lett; 2007 Jul; 111(1):21-5. PubMed ID: 17559946
[TBL] [Abstract][Full Text] [Related]
10. [Expression of the transcription factor PAX5 in childhood acute leukemic cells].
Zhang B; Tie LJ; Ye QD; Gu LJ; Tang JY; Yuan XL; Shen LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):6-10. PubMed ID: 16584581
[TBL] [Abstract][Full Text] [Related]
11. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
[TBL] [Abstract][Full Text] [Related]
12. An unusual case of biphenotypic, bigenotypic mature lymphoma.
Koletsa T; Kotoula V; Christoforidou A; Pantelidou P; Petrakis G; Tsatalas C; Kostopoulos I
J Clin Pathol; 2013 Dec; 66(12):1090-2. PubMed ID: 23794479
[No Abstract] [Full Text] [Related]
13. [Effect of pax5 gene blocked by RNAi on biological characteristics of B cell malignant lymphoma].
Yuan XL; Zhang B; Jiang LM; Shen LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):799-803. PubMed ID: 18718064
[TBL] [Abstract][Full Text] [Related]
14. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
15. Combined heterozygous loss of Ebf1 and Pax5 allows for T-lineage conversion of B cell progenitors.
Ungerbäck J; Åhsberg J; Strid T; Somasundaram R; Sigvardsson M
J Exp Med; 2015 Jun; 212(7):1109-23. PubMed ID: 26056231
[TBL] [Abstract][Full Text] [Related]
16. Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma.
Borson ND; Lacy MQ; Wettstein PJ
Mamm Genome; 2006 Mar; 17(3):248-56. PubMed ID: 16518692
[TBL] [Abstract][Full Text] [Related]
17. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia.
Firtina S; Sayitoglu M; Hatirnaz O; Erbilgin Y; Oztunc C; Cinar S; Yildiz I; Celkan T; Anak S; Unuvar A; Devecioglu O; Timur C; Aydogan G; Akcay A; Atay D; Turkkan E; Karaman S; Orhaner B; Sarper N; Deniz G; Ozbek U
Leuk Res; 2012 Jan; 36(1):87-92. PubMed ID: 21813177
[TBL] [Abstract][Full Text] [Related]
19. B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22).
Johnson RC; Ma L; Cherry AM; Arber DA; George TI
Am J Clin Pathol; 2013 Sep; 140(3):355-62. PubMed ID: 23955454
[TBL] [Abstract][Full Text] [Related]
20. Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis.
Lietz A; Janz M; Sigvardsson M; Jundt F; Dörken B; Mathas S
Br J Haematol; 2007 May; 137(4):342-8. PubMed ID: 17456056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
